CoChat

Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

Open access
Sormani, Maria Pia, Inglese, Matilde, Schiavetti, Irene, Carmisciano, Luca, Laroni, Alice, Lapucci, Caterina, Da Rin, Giorgio, Serrati, Carlo, Gandoglia, Ilaria, Tassinari, Tiziana, Perego, Germana, Brichetto, Giampaolo, Gazzola, Paola, Mannironi, Antonio, Stromillo, Maria Laura, Cordioli, Cinzia, Landi, Doriana, Clerico, Marinella, Signoriello, Elisabetta, Frau, Jessica, Ferrò, Maria Teresa, Di Sapio, Alessia, Pasquali, Livia, Ulivelli, Monica, Marinelli, Fabiana, Callari, Graziella, Iodice, Rosa, Liberatore, Giuseppe, Caleri, Francesca, Repice, Anna Maria, Cordera, Susanna, Battaglia, Mario Alberto, Salvetti, Marco, Franciotta, Diego, Uccelli, Antonio, Maglione, Alessandro, Di Sapio, Alessia, Signori, Alessio, Laroni, Alice, Iovino, Aniello, Repice, Anna Maria, Mannironi, Antonio, Uccelli, Antonio, Serrati, Carlo, Nicoletti, Carolina Gabri, Lapucci, Caterina, Mancinelli, Chiara Rosa, Cordioli, Cinzia, Bezzini, Daiana, Carmagnini, Daniele, Brogi, Davide, Franciotta, Diego, Landi, Doriana, Orazio, Eduardo Nobile, Cocco, Eleonora, Signoriello, Elisabetta, Nako, Enri, Assandri, Ester, Marinelli, Fabiana, Baldi, Federica, Ansaldi, Filippo, Bovis, Francesca, Caleri, Francesca, Siciliano, Gabriele, Cola, Gaia, Perego, Germana, Lus, Giacomo, Brichetto, Giampaolo, Icardi, Giancarlo, bellucci, gianmarco, Rin, Giorgio Da, Marfia, Girolama Alessandra, Vazzoler, Giulia, Liberatore, Giuseppe, Trivelli, Giuseppe, Callari, Graziella, Gandoglia, Ilaria, Maietta, Ilaria, Schiavetti, Irene, Frau, Jessica, Sticchi, Laura, Pasquali, Livia, Lorefice, Lorena, Carmisciano, Luca, Ruggiero, Lucia, Manzino, Marcello, Salvetti, Marco, Bragadin, Margherita Monti, Buscarinu, Maria Chiara, Gagliardi, Maria, Stromillo, Maria Laura, Sormani, Maria Pia, Ferrò, Maria Teresa, Rilla, Maria Teresa, Clerico, Marinella, Battaglia, Mario Alberto, Ponzano, Marta, Fronza, Marzia, Sette, Massimo Del, Inglese, Matilde, Scialabba, Matteo, Bedognetti, Michele, Ulivelli, Monica, De Rossi, Nicola, De Stefano, Nicola, Gazzola, Paola, Bigi, Rachele, Dubbioso, Raffaele, Reniè, Roberta, Iodice, Rosa, Fabbri, Sabrina, Rasia, Sarah, Rolla, Simona, Platzgummer, Stefan, Cordera, Susanna, Tassinari, Tiziana, Carlini, Valentina · 2021 · eBioMedicine
Cited by 227

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background In patients with Multiple Sclerosis (pwMS) disease-modifying therapies (DMTs) affects immune response to antigens. Therefore, post-vaccination serological assessments are needed to evaluate the effect of the vaccine on SARS-CoV-2 antibody response. Methods We designed a prospective multicenter cohort study enrolling pwMS who were scheduled for SARS-Cov-2 vaccination with mRNA vaccines (BNT162b2, Pfizer/BioNTech,Inc or mRNA-1273, Moderna Tx,Inc). A blood collection before the first vaccine dose and 4 weeks after the second dose was planned, with a centralized serological assessment (electrochemiluminescence immunoassay, ECLIA, Roche-Diagnostics). The log-transform of the antibody levels was analyzed by multivariable linear regression. Findings 780 pwMS (76% BNT162b2 and 24% mRNA-1273) had pre- and 4-week post-vaccination blood assessments. 87 (11·2%) were untreated, 154 (19·7%) on ocrelizumab, 25 (3·2%) on rituximab, 85 (10·9%) on fingolimod, 25 (3·2%) on cladribine and 404 (51·7%) on other DMTs. 677 patients (86·8%) had detectable post-vaccination SARS-CoV-2 antibodies. At multivariable analysis, the antibody levels of patients on ocrelizumab (201-fold decrease (95%CI=128–317), p < 0·001), fingolimod (26-fold decrease (95%CI=16–42), p < 0·001) and rituximab (20-fold decrease (95%CI=10–43), p < 0·001) were significantly reduced as compared to untreated patients. Vaccination with mRNA-1273 resulted in a systematically 3·25-fold higher antibody level (95%CI=2·46–4·27) than with the BNT162b2 vaccine ( p < 0·001). The antibody levels on anti-CD20 therapies correlated to the time since last infusion, and rituximab had longer intervals (mean=386 days) than ocrelizumab patients (mean=129 days). Interpretation In pwMS, anti-CD20 treatment and fingolimod led to a reduced humoral response to mRNA-based SARS-CoV-2 vaccines. As mRNA-1273 elicits 3·25-higher antibody levels than BNT162b2, this vaccine may be preferentially considered for patients under anti-CD20 treatment or fingolimod. Combining our data with those on the cellular immune response to vaccines, and including clinical follow-up, will contribute to better define the most appropriate SARS-CoV-2 vaccine strategies in the context of DMTs and MS. Funding FISM[2021/Special-Multi/001]; Italian Ministry of Health‘Progetto Z844A 5 × 1000′.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2021.103581

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Metadata

Authors
Sormani, M. P., Inglese, M., Schiavetti, I., Carmisciano, L., Laroni, A., Lapucci, C., Da Rin, G., Serrati, C., Gandoglia, I., Tassinari, T., Perego, G., Brichetto, G., Gazzola, P., Mannironi, A., Stromillo, M. L., Cordioli, C., Landi, D., Clerico, M., Signoriello, E., Frau, J., Ferrò, M. T., Di Sapio, A., Pasquali, L., Ulivelli, M., Marinelli, F., Callari, G., Iodice, R., Liberatore, G., Caleri, F., Repice, A. M., Cordera, S., Battaglia, M. A., Salvetti, M., Franciotta, D., Uccelli, A., Maglione, A., Di Sapio, A., Signori, A., Laroni, A., Iovino, A., Repice, A. M., Mannironi, A., Uccelli, A., Serrati, C., Nicoletti, C. G., Lapucci, C., Mancinelli, C. R., Cordioli, C., Bezzini, D., Carmagnini, D., Brogi, D., Franciotta, D., Landi, D., Orazio, E. N., Cocco, E., Signoriello, E., Nako, E., Assandri, E., Marinelli, F., Baldi, F., Ansaldi, F., Bovis, F., Caleri, F., Siciliano, G., Cola, G., Perego, G., Lus, G., Brichetto, G., Icardi, G., bellucci, G., Rin, G. D., Marfia, G. A., Vazzoler, G., Liberatore, G., Trivelli, G., Callari, G., Gandoglia, I., Maietta, I., Schiavetti, I., Frau, J., Sticchi, L., Pasquali, L., Lorefice, L., Carmisciano, L., Ruggiero, L., Manzino, M., Salvetti, M., Bragadin, M. M., Buscarinu, M. C., Gagliardi, M., Stromillo, M. L., Sormani, M. P., Ferrò, M. T., Rilla, M. T., Clerico, M., Battaglia, M. A., Ponzano, M., Fronza, M., Sette, M. D., Inglese, M., Scialabba, M., Bedognetti, M., Ulivelli, M., De Rossi, N., De Stefano, N., Gazzola, P., Bigi, R., Dubbioso, R., Reniè, R., Iodice, R., Fabbri, S., Rasia, S., Rolla, S., Platzgummer, S., Cordera, S., Tassinari, T., & Carlini, V.
Venue
eBioMedicine
Publisher
Elsevier BV
Published
2021-10
Volume
72
Pages
103581
ISSN
2352-3964 (ISSN-L)
OpenAlex
W3199233027
Cited by
227
References
6
FWCI
15.40
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. https://app.cochat.ai/papers/10.1016/j.ebiom.2021.103581
The paper
Sormani, M. P., Inglese, M., Schiavetti, I., Carmisciano, L., Laroni, A., Lapucci, C., Da Rin, G., Serrati, C., Gandoglia, I., Tassinari, T., Perego, G., Brichetto, G., Gazzola, P., Mannironi, A., Stromillo, M. L., Cordioli, C., Landi, D., Clerico, M., Signoriello, E., . . . Carlini, V. (2021). Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. eBioMedicine. https://doi.org/10.1016/j.ebiom.2021.103581

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.